About
Allinaire Therapeutics develops humanized monoclonal antibodies targeting EMAP II as potential disease-modifying treatments for cardiopulmonary diseases including pulmonary arterial hypertension, COPD, and acute lung injury.
Explore Allinaire Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.